Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19

BACKGROUND: Use of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) is thought to affect COVID‐19 through modulating levels of angiotensin‐converting enzyme 2, the cell entry receptor for SARS‐CoV2. We sought to assess the association between ACEi/ARB, biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Michael, Vasbinder, Alexi, Anderson, Elizabeth, Catalan, Toniemarie, Shadid, Husam R., Berlin, Hanna, Padalia, Kishan, O’Hayer, Patrick, Meloche, Chelsea, Azam, Tariq U., Khaleel, Ibrahim, Michaud, Erinleigh, Blakely, Pennelope, Bitar, Abbas, Huang, Yiyuan, Zhao, Lili, Pop‐Busui, Rodica, Loosen, Sven H., Chalkias, Athanasios, Tacke, Frank, Giamarellos‐Bourboulis, Evangelos J., Reiser, Jochen, Eugen‐Olsen, Jesper, Hayek, Salim S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075226/
https://www.ncbi.nlm.nih.gov/pubmed/34889102
http://dx.doi.org/10.1161/JAHA.121.023535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075226/
https://www.ncbi.nlm.nih.gov/pubmed/34889102
http://dx.doi.org/10.1161/JAHA.121.023535

Ejemplares similares